Last reviewed · How we verify
Renal transplant rejection
Approved treatments
- Simulect · Astellas Pharma Inc
- Chrft5 · Novartis
- Prograf · Astellas Pharma
Prograf works by inhibiting the activation of T-lymphocytes, a type of immune cell. - Ides · Hansa Biopharma AB
- Muromonab · St. Jude Children's Research Hospital
- Nulojix · Bristol-Myers Squibb
Nulojix blocks the activation of T cells by binding to CD80, preventing an immune response. - Orthoclone Okt3 · Ortho Biotech
- Zenapax · Hoffman-La Roche
- Nulojix · Bristol-Myers Squibb
- Zenapax · National Institute of Neurological Disorders and Stroke (NINDS)
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Renal transplant rejection patent landscape — cliff calendar, originator estates, attackable patents
- Renal transplant rejection treatment landscape brief
- Renal transplant rejection treatment updates RSS
Frequently asked questions about Renal transplant rejection
What drugs treat Renal transplant rejection?
Tracked treatments include Simulect, Chrft5, Prograf, Ides, Muromonab, Nulojix, Orthoclone Okt3, Zenapax.
What is the treatment for Renal transplant rejection?
Standard treatment for Renal transplant rejection includes Simulect, Chrft5, Prograf, Ides, Muromonab. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Renal transplant rejection patent cliff · Renal transplant rejection CI report
- Treatment: Simulect · Astellas Pharma Inc
- Treatment: Chrft5 · Novartis
- Treatment: Prograf · Astellas Pharma
- Treatment: Ides · Hansa Biopharma AB
- Treatment: Muromonab · St. Jude Children's Research Hospital
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing